Welcome to our dedicated page for SPKB news (Ticker: SPKB), a resource for investors and traders seeking the latest updates and insights on SPKB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SPKB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SPKB's position in the market.
Silver Spike Acquisition Corp II announced the redemption of all outstanding Class A ordinary shares effective March 27, 2023, due to the failure to complete an initial business combination within the required period. The redemption will occur at an estimated price of $10.22 per share, reflecting the balance in the Company’s trust account. Following the redemption, the shares will cease trading on March 24, 2023, and the Company will proceed with liquidation. The warrants will expire worthless as there are no redemption rights associated with them. The Company will file for delisting with Nasdaq and terminate its registration under the Securities Exchange Act of 1934.
Silver Spike Acquisition Corp. II (NASDAQ: SPKB/SPKBU/SPKBW) and Eleusis have mutually terminated their planned merger due to unfavorable market conditions. Effective immediately, this decision reflects the current challenges in the market landscape. Silver Spike II will continue to seek a suitable target for an initial business combination. A Current Report on Form 8-K will provide further details to the U.S. Securities and Exchange Commission. Eleusis focuses on transforming psychedelics into mainstream medicine, while Silver Spike II aims to operate in the cannabis and wellness sectors.
Eleusis Holdings Ltd has received a Notice of Allowance from the US Patent and Trademark Office for its proprietary psilocin salt form and formulations, marking a significant step for its lead drug candidate, ELE-Psilo. Designed for intravenous delivery, ELE-Psilo targets major depressive disorder and aims to provide consistent and controllable treatment. The company plans to initiate clinical trials in the UK in 2022. Furthermore, Eleusis has signed a definitive business combination agreement with Silver Spike Acquisition Corp. II (NASDAQ: SPKB/SPKBU/SPKBW), moving towards becoming a public company.
Silver Spike Acquisition Corp II has priced its IPO at $10.00 per unit, raising a total of $250 million through the sale of 25 million units. The units will trade on Nasdaq under the symbol 'SPKBU' starting March 11, 2021. Each unit contains one Class A ordinary share and one-fourth of a redeemable warrant, with the whole warrant priced at $11.50 per share. The company aims to merge with businesses in the cannabis sector that comply with legal standards. Credit Suisse and Stifel are managing the offering, which includes a 45-day option for underwriters to purchase additional units.
FAQ
What is the market cap of SPKB (SPKB)?
